Atherosclerosis
Volume 192, Issue 2 , Pages 243-245 , June 2007

Resialylation of sialic acid deficit vascular endothelium, circulating cells and macromolecules may counteract the development of atherosclerosis: A hypothesis

Received 6 December 2006 ,Revised 28 February 2007 ,Accepted 8 March 2007.

References 

  1. Lindberg G, Råstam L, Gullberg B, Lundblad A, Nilsson-Ehle P, Hanson BS. Serum concentrations of total sialic acid and sialoglycoproteins in relation to coronary heart disease risk markers. Atherosclerosis. 1993;103:123–129
  2. Schauer R. Chemistry, metabolism, and biological functions of sialic acids. Adv Carbohydr Chem Biochem. 1982;40:131–234
  3. Görög P, Born GV. Uneven distribution of sialic acids on the luminal surface of aortic endothelium. Br J Exp Pathol. 1983;64:418–424
  4. Görög P, Schraufstätter I, Born GVR. Effect of removing sialic acids from endothelium on the adherence of circulating platelets on arteries in vivo. Proc R Soc Lond B Biol Sci. 1982;214:471–480
  5. Görög P, Born GVR. Increase uptake of circulating LDL and fibrinogen by arterial walls after removal of sialic acids from their endothelial surface. Br J Exp Path. 1982;63:447–451
  6. Orekhov AN, Tertov VV, Mukhin DN, Mikhailenko IA. Modification of low density lipoprotein by desialylation causes lipid accumulation in cultured cells: discover of desialylated lipoprotein with altered cellular metabolism in the blood of atheroclerotic patients. Biochem Biophys Res Commun. 1989;162:206–211
  7. Bastida E, Monteagudo J, Ordinas A, De Marco L, Castillo R. Asialo von Willebrand factor enhances platelet adhesion to vessel subendothelium. Thromb Haemost. 1988;60:30–34
  8. Hadengue A, Razavian SM, Del-Pino M, Simon A, Levenson J. Influence of sialic acid on erythrocyte aggregation in hypercholesterolemia. Thromb Haemostas (Stuttgart). 1996;76:944–949
  9. Lindberg G, Eklund GA, Gullberg B, Råstam L. Serum sialic acid concentration and cardiovascular mortality. BMJ. 1991;302:143–146
  10. Lindberg G, Råstam L, Gullberg B, Eklund GA. Serum sialic acid concentration predicts both coronary heart disease and stroke mortality: multivariate analysis including 54, 385 men and women during 20.5 years follow-up. Int J Epidemiol. 1992;21:253–257
  11. Råstam L, Lindberg G, Folsom AR, Burke GL, Nilsson-Ehle P, Lundblad A. Association between serum sialic acid concentration and carotid atherosclerosis measured by B-mode ultrasound. Int J Epidemiol. 1996;22:953–958
  12. Knuiman MW, Watts GF, Divitini ML. Is sialic acid an independent risk factor for cardiovascular disease? A 17-year follow-up study in Busselton. Western Austr Ann Epidemiol. 2004;14:627–632
  13. Watts GF, Crook MA, Haq S, Mandalia S. Serum sialic acid as an indicator of change in coronary artery disease. Metabolism. 1995;44:147–148
  14. Gracheva EV, Samovilova NN, Golovanova NK, et al. Sialyltransferase activity of human plasma and aortic intima is enhanced in atherosclerosis. Biochim Biophys Acta. 2002;1586:123–128
  15. Resnitzky P, Yaari A, Danon . Biophysical characteristies of erythrocytes during acute myocardial infarction and venous thrombosis. Thromb Diath Haemorrh. 1972;28:524–532
  16. Kelm S, Shukla AK, Paulson JC, Schauer R. Reconstitution of the masking effect of sialic acid groups on sialidase-treated erythrocytes by the action of sialyltransferases. Carbohydr Res. 1986;149:59–64
  17. Helin-Salmivaara A, Virtanen A, Vesalainen R, et al. NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland. Eur Heart J. 2006;27:1635–1636
  18. Bresalier RS, Sandler RS, Quan H, et al. Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352:1092–1102
  19. Solomon SD, McMurray JJ, Pfeffer MA, et al. Adenoma prevention with celecoxib (APC) study investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005;352:1071–1080
  20. Antman EM, DeMets D, Loscalzo J. Cyclooxygenase inhibition and cardiovascular risk. Circulation. 2005;112:759–770
  21. FitzGerald GA, Sherry S. Pharmacology and pharmacokinetics of platelet-active drugs under current clinical investigation. Adv Prostaglandin Thromboxane Leukot Res. 1982;10:107–172
  22. Strong JP, Malcom GT, McMahan CA, et al. Prevalence and extent of atherosclerosis in adolescents and young adults: implications for prevention from the pathobiological determinants of atherosclerosis in youth study. JAMA. 1999;281:727–735

PII: S0021-9150(07)00177-3

doi: 10.1016/j.atherosclerosis.2007.03.011

Atherosclerosis
Volume 192, Issue 2 , Pages 243-245 , June 2007

Article Tools